Slide 1: Third Quarter 2021 Operating & Financial Results Conference Call
Third quarter 2021 Operating & Financial Results Conference Call / Webinar November 1st, 2021 4:30 PM Eastern
Slide 2: Today's Speakers
TODAY’S SPEAKERS Panna Sharma David Margrave Dr. Kishor Bhatia Nicole Leber Chief Executive Officer, Chief Financial Officer Chief Scientific Officer Finance and President and Director and Secretary Administration NASDAQ:LTRN 1
Slide 3: Forward Looking Statements
LTRN Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, stateme
Slide 4: Contents
Contents 01 Lantern Highlights 02 Financial Overview 03 R&D Updates 04 Q&A NASDAQ:LTRN 3
Slide 5: A quarter of meaningful progress for Lantern Pharma on multiple fronts
A quarter of meaningful progress for Lantern Pharma on multiple fronts CLINICAL OPERATIONAL RADR® DISCOVERY PROGRESS PROGRESS PLATFORM EFFORTS NASDAQ:LTRN 4
Slide 6: RADR Surpassed 10 billion datapoints this past month
RADR® Surpassed 10 billion datapoints this past month (x10 increase since Nov. 2020) accelerate drug uncover new therapeutic develop insights into the creation of expand our ability to collaborate development timelines opportunities combination-therapy programs with additional partners NASDAQ:LTRN 5
Slide 7: What is RADR: Response Algorithm for Drug Positioning & Rescue
What is RADR ® Response Algorithm for A proprietary integrated data analytics, experimental biology, oncology-focused, machine-learning-based platform Drug Positioning & Rescue focused on drug development Leverages cutting edge machine-learning approaches and techniques to generate powerful data-dri
Slide 8: 3rd Quarter 2021 and Subsequent Highlights
3rd Quarter 2021 and Subsequent Highlights • Achieved over 10 billion data points on our A.I. platform, RADR® • LP-184 granted Orphan Drug Designation for the treatment of pancreatic cancer, glioblastoma multiforme (GBM) and other malignant gliomas by the U.S. Food and Drug Administration (FDA) • An
Slide 9: Lantern leverages A.I. to reduce oncology drug development costs and improve likelihood of success
Lantern leverages A.I. to reduce oncology drug development costs and improve the likelihood of success Abandoned Drug Assets & New Drug Development RADR® Responders Non-Responders • Drugs that fell short of statistical • Big data (genomic, clinical, response) • Patient stratification based on A.I. e
Slide 10: Growing A.I. platform to uncover new therapeutic opportunities
We plan on continuing further data expansion by incorporating and curating additional datasets from proprietary studies and public data sources and further automating the evolution of RADR’s library of algorithms. Additionally, Lantern will be augmenting the 10.4 billion datapoints with additional d
Slide 11: Lantern's Unique & Rapidly Developing Pipeline
Lantern’s Unique & Rapidly Developing Pipeline Indication Program R&D Preclinical Phase I Phase II Phase III Prostate Cancer LP-100 Initial 9 patients showed median (Metastatic Castration-Resistant Prostate Cancer) (Irofulven) overall survival (mOS) of 12.5 months Non-Small Cell Lung Cancer LP-300 T
Slide 12: LP-184 Positive preclinical data in pancreatic cancer
LP-184 Positive preclinical data in pancreatic cancer Highlights Upcoming Milestones • Granted Orphan Drug Designation by FDA • Initiate Investigational New drug (IND) and Phase 1 human trial • Positive preclinical data in pancreatic cancers that have either high levels of PTGR1 • Host virtual Key O
Slide 13: LP-184 cytotoxic activity is driven by PTGR1, as predicted by RADR
As predicted by RADR ®, LP-184 cytotoxic activity is driven by PTGR1 RADR Insight (in-silico) In-vitro Gene Editing Studies (CRISPR) Panc03.27 sgControl Panc03.27 sg PTGR1 Capan-1 sgControl Capan-1 sg PTGR1 1 Pancreatic cancer cell line viability 0.8 0.6 0.4 0.2 0 0 200 400 600 800 1000 LP-184 test
Slide 14: Positive Preclinical Data in Pancreatic Cancer
Positive Preclinical Data in Pancreatic Cancer LP-184 in vivo response in a Capan-1 LP-184 demonstrated significant tumor shrinkage (146x) in pancreatic cancer xenograft mouse model in-vivo mice PDX models 600 Vehicle control LP-184 (3 mg/ kg) 500 Tumors From Vehicle Control Mice at the End 400 Tumo
Slide 15: LP-184 shows nanomolar in vitro potency in pancreatic cancer cell lines
LP-184 shows nanomolar in vitro potency in pancreatic cancer cell lines Drug / Range of IC50 Median 800 Compounds [nM] across 6 IC50 [nM] cancer cell lines 600 LP-184 100 - 200 154 LP-184 IC50 [nM] 400 Gemcitabine 30 - 1,000 149 Irinotecan 3,000 - 12,052 70,000 200 5-Fluorouracil 30,000 - 72,747 300
Slide 16: LP-184 Anticipated Upcoming Milestones
LP-184 Anticipated Upcoming Milestones • In discussions on the design of first-in-human clinical studies for LP-184 in collaboration with Dr. Igor Astsaturov and other key opinion leaders in the pancreatic cancer treatment landscape. • Initiate IND application enabling animal studies later this year
Slide 17: KOL event on Nov. 18th, World Pancreatic Cancer day
KOL event on Nov. 18th , World Pancreatic Cancer day Virtual Key Opinion Leader(KOL) event on LP-184 for the treatment of pancreatic cancer Speakers Save the date on November 18th Dr. Igor Astsaturov Dr. Kishor G. Bhatia #LightupthePurple Lantern P h a r m a Co-leader of the Marvin & Chief Scientifi
Slide 18: LP-184 Positive preclinical data in Glioblastoma (GBM)
LP-184 Positive preclinical data in Glioblastoma(GBM) Highlights Upcoming Milestones • Completed a successful preclinical study • Share detailed scientific results from LP-184 demonstrating the ability of LP-184 to inhibit collaborative research program in GBM after tumor growth and improve survival
Slide 19: LP-184 shows complete tumor regression in mice implanted with Glioblastoma
LP-184 shows complete tumor regression in mice implanted with Glioblastoma in multiple models U87-MG GBM Model M1123 GBM Model 500 500 Orthotopic Subcutaneous Xenograft 450 Neurospheres Patient Derived 450 400 400 Tumor volume (mm3) Tumor volume (mm3) 350 350 300 300 250 250 200 200 150 150 100 100
Slide 20: Antibody-drug Conjugates (ADC) - an area of increasing future focus
Antibody-drug Conjugates (ADC) - an area of increasing future focus of Lantern Pharma novel class of highly potent biological drugs conjugate a cytotoxic drug with a monoclonal antibody Antibody-Drug Conjugates (ADCs) (mAb) through an applicable linker High specificity • ADCs take advantage of the h
Slide 21: Collaboration with Deep Lens A.I. Clinical Trial Machine, VIPER
Collaboration with Deep Lens A.I. Clinical Trial Machine, VIPER strategic collaboration to accelerate patient enrollment for Phase 2 clinical trial for never-smokers with Lantern Pharma X DeepLens non-small cell lung cancer (NSCLC), utilizing LP-300 in combination with chemotherapy Help Patients to
Slide 22: Collaboration with Code Ocean's Compute Capsule
Collaboration with Code Ocean’s Compute Capsule strategic collaboration to to facilitate the accelerated development of RADR® Lantern Pharma X Code Ocean while reducing development complexity and cost and increasing security and reproducibility Leveraging Code Ocean’s Further enhances our already Co
Slide 23: Anticipated Upcoming Milestones
Anticipated Upcoming Milestones • Host virtual Key Opinion Leader (KOL) event on LP-184 for the treatment of pancreatic cancer on World Pancreatic Cancer Day • Planned launch of 90 patient Phase 2 clinical trial in the US for LP-300 in NSCLC focused on never- smokers that are chemo naïve and failed/
Slide 24: Contents
Contents 01 Lantern Highlights 02 Financial Overview 03 R&D Updates 04 Q&A 23
Slide 25: Summary Results of Operations
Summary Results of Operations Three Months Ended Nine Months Ended September 30, September 30, (Unaudited) (Unaudited) 2021 2020 2021 2020 Operating expenses: General and administrative 1,184,486 1,100,719 3,671,945 2,117,290 Research and development 2,964,391 600,769 5,408,320 894,896 Total operati
Slide 26: Balance Sheet Highlights & Summary
Balance Sheet Highlights & Summary 9/30/2021 12/31/2020 (unaudited) Cash, Cash equivalents and Marketable Securities $ 73,832,553 $ 19,229,232 Prepaid Expenses & Other Current Assets $ 2,504,089 $ 1,007,690 Total Assets $ 77,606,197 $ 20,359,634 Total Liabilities $ 1,877,623 $ 660,839 Total Stockhol
Slide 27: Shares Outstanding
Shares Outstanding September 30, 2021 LANTERN PHARMA INC. (LTRN) Common Shares Outstanding 11,186,999 Warrants 298,204 Options (Employees, Management and Directors) 801,588 Fully Diluted Shares Outstanding 12,286,791 NASDAQ:LTRN 26
Slide 28: We believe our solid financial position will fuel continued growth
“ We believe our solid financial position will fuel continued growth and evolution of our RADR® A.I. platform, accelerate the development of our portfolio of targeted oncology drug candidates and allow us to introduce additional targeted product and collaboration opportunities in a capital efficient
Slide 29: Contents
Contents 01 Lantern Highlights 02 Financial Overview 03 R&D Updates 04 Q&A 28
Slide 30: LP-184 and LP-284 targets NER deficient cells
LP-184 and LP-284 targets NER deficient cells Mutant cell lines deficient in the Nucleotide Excision Repair (NER) pathway were more sensitive to LP-184/ LP-284 than the parent cell line NASDAQ:LTRN 29
Slide 31: LP-184 is effective in multiple HR deficient prostate cancer models
LP-184 is effective in multiple HR deficient prostate cancer models PC3M metastatic prostate cancer cell line LP-184 and PARP inhibitor Olaparib are equipotent in vitro in the parental PC3M cell line. LP-184 is 8X more active than Olaparib in the BRCA2 depleted PC3M line. LP-184 Olaparib NASDAQ:LTRN
Slide 32: LP-184 is effective in a xenograft model of ATRT
LP-184 is effective in a xenograft model of Atypical Teratoid/ Rhabdoid Tumor (ATRT) Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) applications submitted for the use of LP-184 in ATRT treatment CHLA06 subcutaneous cell line derived xenograft model (SMARCB1 deletion, MYC
Slide 33: LP-184 CNS Bioavailability
LP-184 CNS Bioavailabiity NASDAQ:LTRN 32
Slide 34: A Transformational year for Lantern
2022 A Transformational year for Lantern • Launch of multiple human clinical trials over the next 12 months • Ongoing growth of our RADR platform – Reach 20 billion datapoints during 2022. • With our network of strategic collaborators and recent additions to our team, we believe we are very well pos
Slide 35: Contents
Contents 01 Lantern Highlights 02 Financial Overview 03 R&D Updates 04 Q&A 34
Slide 36: www.lanternpharma.com IR Contact
www.lanternpharma.com @LanternPharma Nasdaq: LTRN IR Contact: IR@lanternpharma.com 1-212-671-1021